Akari Therapeutics (AKTX)
(Delayed Data from NSDQ)
$3.22 USD
+0.06 (1.90%)
Updated Sep 20, 2024 11:01 AM ET
3-Hold of 5 3
D Value B Growth NA Momentum NA VGM
Balance Sheet
Fiscal Year End for Akari Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 13 | 9 | 14 | 6 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 1 | 1 |
Total Current Assets | 4 | 14 | 12 | 15 | 7 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 4 | 14 | 12 | 15 | 7 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 3 | 3 | 2 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 8 | 0 | 0 | 0 |
Total Current Liabilities | 5 | 12 | 5 | 5 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5 | 12 | 6 | 5 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 0 | 0 | 32 |
Capital Surplus | 175 | 167 | 153 | 140 | 111 |
Retained Earnings | -227 | -217 | -200 | -182 | -144 |
Other Equity | 51 | 51 | 52 | 52 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 0 | 2 | 6 | 9 | -2 |
Total Liabilities & Shareholder's Equity | 4 | 14 | 12 | 15 | 7 |
Total Common Equity | 0 | 2 | 6 | 9 | -2 |
Shares Outstanding | 6.60 | 3.70 | 2.60 | 1.90 | 0.70 |
Book Value Per Share | -0.03 | 0.48 | 2.13 | 4.94 | -2.53 |
Fiscal Year End for Akari Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 1 | 4 | -99,999 | -99,992 |
Receivables | 0 | 0 | 0 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 1 | 1 | 1 | NA | 1 |
Total Current Assets | 5 | 3 | 4 | NA | 8 |
Net Property & Equipment | 0 | 0 | 0 | NA | NA |
Investments & Advances | 0 | 0 | 0 | NA | NA |
Other Non-Current Assets | 0 | 0 | 0 | NA | NA |
Deferred Charges | 0 | 0 | 0 | NA | NA |
Intangibles | 0 | 0 | 0 | NA | 0 |
Deposits & Other Assets | 0 | 0 | 0 | NA | NA |
Total Assets | 5 | 3 | 4 | NA | 8 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 1 | 0 | 0 | NA | NA |
Accounts Payable | 5 | 3 | 2 | NA | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 2 | 2 | 2 | NA | 2 |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 1 | 2 | 1 | NA | 2 |
Total Current Liabilities | 9 | 6 | 5 | NA | 5 |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 0 | 0 | 0 | NA | NA |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 0 | NA | NA |
Other Non-Current Liabilities | 0 | 0 | NA | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | NA |
Total Liabilities | 9 | 6 | 5 | NA | 5 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | NA | NA |
Common Stock (Par) | 2 | 2 | 1 | NA | 1 |
Capital Surplus | 183 | 176 | 175 | NA | 171 |
Retained Earnings | -241 | -233 | -227 | NA | -220 |
Other Equity | 51 | 51 | 51 | NA | 51 |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | -4 | -4 | 0 | NA | 3 |
Total Liabilities & Shareholder's Equity | 5 | 3 | 4 | NA | 8 |
Total Common Equity | -4 | -4 | 0 | 0 | 100,002 |
Shares Outstanding | 12.10 | 7.90 | 6.60 | 5.60 | 3.70 |
Book Value Per Share | -0.31 | -0.45 | -0.03 | 0.00 | 27,027.51 |